^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)

    i
    Other names: E/C/F/TAF
    Associations

    News

    Trials
    Company:
    Gilead
    Drug class:
    Cytochrome P450 inhibitor, Integrase inhibitor, Nucleoside analog reverse transcriptase inhibitor
    Related drugs:
    Associations

    News

    Trials
    15d
    B-free Multistage Trial (clinicaltrials.gov)
    P4, N=210, Enrolling by invitation, Insel Gruppe AG, University Hospital Bern | Trial completion date: Dec 2027 --> Sep 2027 | Trial primary completion date: Nov 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
    2ms
    Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (clinicaltrials.gov)
    P2/3, N=129, Active, not recruiting, Gilead Sciences | Trial completion date: Dec 2024 --> Jun 2025
    Trial completion date
    |
    Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
    3ms
    A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (clinicaltrials.gov)
    P4, N=350, Recruiting, Gilead Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tybost (cobicistat) • Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) • ritonavir
    7ms
    Bictegravir in the Elderly Living With HIV (BICEP) (clinicaltrials.gov)
    P=N/A, N=162, Active, not recruiting, State University of New York at Buffalo | Trial completion date: Jul 2023 --> Dec 2024 | Trial primary completion date: Jul 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
    9ms
    A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (clinicaltrials.gov)
    P4, N=350, Not yet recruiting, Gilead Sciences
    New P4 trial
    |
    Tybost (cobicistat) • Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) • ritonavir
    1year
    B-free Multistage Trial (clinicaltrials.gov)
    P4, N=210, Enrolling by invitation, Insel Gruppe AG, University Hospital Bern | Recruiting --> Enrolling by invitation | Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: Aug 2025 --> Nov 2025
    Enrollment status • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)